Moonlake Immunotherapeutics Form 4 insider transactions

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 1,100 shares of common stock on July 27, 2026 for $20.00 per share.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 52,448 shares of common stock on July 21, 2026.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 43,700 shares of common stock on July 20, 2026 for $20.09 per share.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 16,105 shares of common stock on July 15, 2026 for $20.01 per share.

Da Silva Jorge Santos, Chief Executive Officer and a Director of MoonLake Immunotherapeutics, sold 102,225 shares of common stock on July 9, 2026.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 47,775 shares of Class A ordinary shares for approximately $20.03 per share, executed under a pre-arranged trading plan.

MoonLake Immunotherapeutics reports that its Chief Financial Officer, Matthias Bodenstedt, sold a portion of his Class A ordinary shares through a pre-arranged trading plan.

MoonLake Immunotherapeutics reports a Form 4 filing detailing the acquisition of stock options by Director Andrew John Phillips.

Director Spike Loy of MoonLake Immunotherapeutics acquired options to purchase 22,195 Class A ordinary shares, with vesting contingent on continued service.

Catherine Moukheibir, a Director at MoonLake Immunotherapeutics, has acquired stock options as part of her compensation.

MoonLake Immunotherapeutics reports that Director Xavier Ramnik acquired stock options for 22,195 shares.

Chief Scientific Officer Kristian Reich sold 150,000 Class A ordinary shares of MoonLake Immunotherapeutics via a 10b5-1 plan.

MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold shares valued at approximately $20.02 per share under a Rule 10b5-1 trading plan.

MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 2,426 shares of Class A common stock via a 10b5-1 trading plan.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva reported the sale of Class A ordinary shares totaling 150,000 shares across two transactions in early April 2026.

MoonLake Immunotherapeutics' Chief Financial Officer, Matthias Bodenstedt, has sold a significant number of Class A ordinary shares under a pre-arranged trading plan.

MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, was granted 354,296 Class A ordinary shares as restricted stock, vesting over four years, aligning his interests with long-term company performance.

MoonLake Immunotherapeutics' CEO, Jorge Santos da Silva, was granted 520,342 stock options with an exercise price of $11.29, vesting over four years.

MoonLake Immunotherapeutics' Chief Scientific Officer, Kristian Reich, was granted 520,342 stock options with an exercise price of $11.29, vesting over four years.

MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, converted MoonLake AG common shares into Class A ordinary shares of the Issuer, increasing his direct beneficial ownership.

MoonLake Immunotherapeutics' Chief Scientific Officer, Kristian Reich, converted MoonLake AG common shares into Class A ordinary shares of the Issuer, increasing his direct beneficial ownership.

MoonLake Immunotherapeutics CEO, Jorge Santos da Silva, converted MoonLake AG common shares into 196,316 Class A ordinary shares of the issuer.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 200,000 Class A ordinary shares in two transactions to cover tax liabilities and related expenses.

MoonLake Immunotherapeutics' Chief Scientific Officer, Kristian Reich, sold over 200,000 Class A ordinary shares to cover tax liabilities and related expenses.

MoonLake Immunotherapeutics' Chief Financial Officer, Matthias Bodenstedt, purchased 10,870 Class A ordinary shares for approximately $9.09 per share.

Cormorant Asset Management and affiliated funds reported significant sales of MoonLake Immunotherapeutics Class A Ordinary Shares across multiple transactions in late September 2025.

MoonLake Immunotherapeutics' Chief Scientific Officer, Kristian Reich, converted MoonLake AG common shares into Class A ordinary shares of the issuer, increasing his direct beneficial ownership.

Catherine Moukheibir, a Director at MoonLake Immunotherapeutics, exercised options to acquire 23,500 Class A ordinary shares and subsequently sold all acquired shares for a weighted average price of $48.79 per share.

A group of investment entities led by BVF Partners L.P. and Mark N. Lampert have filed a Form 4 detailing their substantial beneficial ownership and derivative securities in MoonLake Immunotherapeutics (MLTX), including director option grants.

MoonLake Immunotherapeutics Director Simon Sturge was granted options to purchase 6,682 Class A ordinary shares as part of his compensation.